Search

Your search keyword '"Reis-Filho, Jorge S."' showing total 2,550 results

Search Constraints

Start Over You searched for: Author "Reis-Filho, Jorge S." Remove constraint Author: "Reis-Filho, Jorge S."
2,550 results on '"Reis-Filho, Jorge S."'

Search Results

151. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary

153. Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas

154. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers

155. Spatial analyses of immune cell infiltration in cancer: current methods and future directions:A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

156. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer:A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

157. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

158. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

159. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer:a report of the international immuno-oncology biomarker working group

160. Decreased HER2 expression in endometrial cancer following anti‐HER2 therapy.

161. KIT genetic alterations in breast cancer.

162. A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

163. Abstract 2132: Tumor heterogeneity of CCNE1 copy number assessed by fluorescence in situ hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression

164. Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

165. Data from Cancer-Causative Mutations Occurring in Early Embryogenesis

166. Abstract 6063: Genomic characterization of non-small cell lung cancer (NSCLC) brain metastasis (BM) patients identifies novel alterations associated with tropisms and disease progression

167. Data from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

168. Abstract 5721: Automated annotation for large-scale clinicogenomic models of lung cancer treatment response and overall survival

169. Abstract 6421: Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)

170. Supplementary Data from Cancer-Causative Mutations Occurring in Early Embryogenesis

171. Data from Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

172. Data from V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer

173. Data from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

174. Data from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

175. Supplementary Data from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

176. Supplementary Table 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

177. Press Conference from Functional Viability Profiles of Breast Cancer

178. Supplementary Data PDF from Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

179. Supplementary Figures 1-12, Supplementary Tables 1-3 from AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin Signaling

180. Supplementary file - liver genes from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

181. Data from Functional Viability Profiles of Breast Cancer

182. Supplementary Data from V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer

183. Supplementary Fig 3 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

184. Supplementary Fig 1 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

185. Supplementary Fig 4 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

186. Data from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

187. Supplementary Figure from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

188. Supplementary Fig 6 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

189. Supplementary Figures 1-8, Tables 1-9 from Functional Viability Profiles of Breast Cancer

190. Supplementary methods, tables and figures. from Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

191. Supplementary Fig 5 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

192. Data from INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors

193. Supplementary Fig 2 from HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

194. Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles

196. Molecular Biomarkers of Disease Outcomes and Mechanisms of Acquired Resistance to First-Line Osimertinib in Advanced EGFR-Mutant Lung Cancers

197. Supplementary Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles

199. Supplementary Tables from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

Catalog

Books, media, physical & digital resources